Sparkling turquoise waters, sugar-white beaches and mouthwatering gastronomy are just some of the reasons the Greek islands ...

Greek authorities rescued 545 migrants from a vessel off Gavdos Friday, one of the largest recent operations as arrivals from ...

Tata Motors has launched its reborn Sierra at Rs 11.49 lakh, directly challenging the Hyundai Creta. The base Sierra Smart+ boasts superior features and larger dimensions compared to the Creta E, ...

As of now, Tata has announced the price of only the entry-level variant of the Sierra 2025. While the SUV starts at Rs 11.49 lakh (ex-showroom), prices of the remaining variants will be announced next ...

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) ranks among the most oversold biotech stocks to invest in. On November 20, Leerink Partners upgraded Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) from Market ...

Crete’s sheer size can make deciding where to go a little daunting. This guide can help you decide which side of the island—from its rugged west to its less explored eastern reaches—is right for you.

Shares of Agios Pharmaceuticals (AGIO) bounced back with a ~10% rise on Thursday as Leerink Partners upgraded the biotech, arguing that the stock, which dropped over 50% in the previous session in ...

Despite missing a key endpoint, there's still likely to be value in mitapavit. Management plans for a marketing application early in 2026. The trial was designed with two primary endpoints, and it hit ...

Shares of Agios Pharmaceuticals (AGIO) plunged ~45% in the premarket on Wednesday after the biotech announced a mixed outcome from a late-stage trial for its lead asset mitapivat in sickle cell ...

In its mission to grow the reach of its pyruvate kinase (PK) activator Pyrukynd (mitapivat), Agios Pharmaceuticals has come up short of producing an unequivocal win in the key indication of sickle ...

Trial met primary endpoint of hemoglobin response and key secondary endpoints of change from baseline in hemoglobin concentration and indirect bilirubin Trial showed trend favoring mitapivat but did ...